Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Skin Neoplasms | 10 | 2018 | 1679 | 1.99 | Why? |
| Melanoma | 6 | 2019 | 1229 | 1.70 | Why? |
| Keratinocytes | 2 | 2018 | 119 | 1.38 | Why? |
| Fibroblasts | 2 | 2018 | 839 | 1.07 | Why? |
| Germ-Line Mutation | 2 | 2018 | 86 | 0.92 | Why? |
| Rosacea | 1 | 2021 | 57 | 0.82 | Why? |
| Tetracyclines | 1 | 2020 | 82 | 0.82 | Why? |
| Basal Cell Nevus Syndrome | 1 | 2018 | 4 | 0.78 | Why? |
| Pigmentation Disorders | 1 | 2019 | 29 | 0.77 | Why? |
| Incontinentia Pigmenti | 1 | 2018 | 10 | 0.77 | Why? |
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 45 | 0.76 | Why? |
| Aquaporin 3 | 1 | 2018 | 1 | 0.76 | Why? |
| Genistein | 1 | 2018 | 25 | 0.76 | Why? |
| alpha-Tocopherol | 1 | 2018 | 37 | 0.76 | Why? |
| Keratosis | 1 | 2018 | 16 | 0.74 | Why? |
| Hypopigmentation | 1 | 2018 | 28 | 0.74 | Why? |
| MAP Kinase Signaling System | 2 | 2019 | 360 | 0.73 | Why? |
| Anticarcinogenic Agents | 1 | 2018 | 25 | 0.73 | Why? |
| Keratoderma, Palmoplantar | 1 | 2018 | 24 | 0.72 | Why? |
| Dermatofibrosarcoma | 1 | 2017 | 5 | 0.72 | Why? |
| Rare Diseases | 2 | 2019 | 373 | 0.70 | Why? |
| Mycosis Fungoides | 2 | 2016 | 48 | 0.70 | Why? |
| Acne Vulgaris | 1 | 2021 | 198 | 0.69 | Why? |
| Vitiligo | 1 | 2018 | 76 | 0.69 | Why? |
| Heterozygote | 1 | 2018 | 249 | 0.69 | Why? |
| Ear Cartilage | 1 | 2016 | 2 | 0.65 | Why? |
| Estradiol | 1 | 2018 | 250 | 0.63 | Why? |
| Foot Dermatoses | 1 | 2018 | 112 | 0.63 | Why? |
| Carcinoma, Basal Cell | 1 | 2018 | 144 | 0.63 | Why? |
| Ear Auricle | 1 | 2016 | 62 | 0.61 | Why? |
| Ear Diseases | 1 | 2016 | 58 | 0.59 | Why? |
| Cell Movement | 1 | 2018 | 695 | 0.56 | Why? |
| Vasculitis | 1 | 2021 | 691 | 0.53 | Why? |
| Water | 1 | 2018 | 765 | 0.50 | Why? |
| Skin Diseases | 2 | 2020 | 2509 | 0.47 | Why? |
| Skin | 3 | 2021 | 2096 | 0.43 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.39 | Why? |
| Craniofacial Abnormalities | 2 | 2019 | 33 | 0.37 | Why? |
| Antioxidants | 1 | 2018 | 1593 | 0.36 | Why? |
| Receptors, Dopamine D3 | 2 | 2017 | 4 | 0.35 | Why? |
| Mesencephalon | 2 | 2017 | 12 | 0.35 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.33 | Why? |
| Dopaminergic Neurons | 2 | 2017 | 59 | 0.32 | Why? |
| Neuronal Plasticity | 2 | 2017 | 98 | 0.32 | Why? |
| Biological Therapy | 2 | 2021 | 456 | 0.31 | Why? |
| Dyskinesia, Drug-Induced | 2 | 2017 | 20 | 0.30 | Why? |
| Programmed Cell Death 1 Receptor | 2 | 2017 | 724 | 0.24 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.22 | Why? |
| Sex Distribution | 2 | 2018 | 2083 | 0.22 | Why? |
| Italy | 12 | 2021 | 38444 | 0.21 | Why? |
| Chediak-Higashi Syndrome | 1 | 2019 | 1 | 0.20 | Why? |
| rab27 GTP-Binding Proteins | 1 | 2019 | 2 | 0.20 | Why? |
| Piebaldism | 1 | 2019 | 3 | 0.20 | Why? |
| Skin Abnormalities | 1 | 2019 | 5 | 0.20 | Why? |
| Hair | 2 | 2019 | 175 | 0.20 | Why? |
| Hypertrichosis | 1 | 2019 | 5 | 0.20 | Why? |
| Neurocutaneous Syndromes | 1 | 2019 | 6 | 0.20 | Why? |
| Iris | 1 | 2019 | 27 | 0.19 | Why? |
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 92 | 0.19 | Why? |
| Genetic Predisposition to Disease | 3 | 2018 | 4027 | 0.19 | Why? |
| Neoplasm Staging | 2 | 2017 | 1999 | 0.19 | Why? |
| Heredity | 1 | 2018 | 37 | 0.19 | Why? |
| Abnormalities, Multiple | 1 | 2019 | 75 | 0.19 | Why? |
| Menkes Kinky Hair Syndrome | 1 | 2017 | 1 | 0.19 | Why? |
| Asbestos | 1 | 2018 | 45 | 0.19 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.18 | Why? |
| Ubiquitin Thiolesterase | 1 | 2018 | 69 | 0.18 | Why? |
| Lipid Peroxidation | 1 | 2018 | 114 | 0.18 | Why? |
| Phenotype | 2 | 2021 | 4037 | 0.18 | Why? |
| I-kappa B Kinase | 1 | 2018 | 98 | 0.18 | Why? |
| Mesothelioma | 1 | 2018 | 76 | 0.18 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.18 | Why? |
| Hair Diseases | 1 | 2017 | 31 | 0.17 | Why? |
| Epilepsies, Partial | 1 | 2017 | 44 | 0.17 | Why? |
| Receptors, Dopamine D2 | 1 | 2017 | 22 | 0.17 | Why? |
| Finasteride | 1 | 2017 | 29 | 0.17 | Why? |
| Tumor Suppressor Proteins | 1 | 2018 | 165 | 0.17 | Why? |
| Europe, Eastern | 1 | 2017 | 88 | 0.17 | Why? |
| Receptors, Estrogen | 1 | 2018 | 171 | 0.17 | Why? |
| Facial Dermatoses | 1 | 2021 | 222 | 0.17 | Why? |
| Pedigree | 1 | 2018 | 502 | 0.17 | Why? |
| 5-alpha Reductase Inhibitors | 1 | 2017 | 30 | 0.17 | Why? |
| Growth Disorders | 1 | 2017 | 91 | 0.16 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.16 | Why? |
| Mohs Surgery | 1 | 2017 | 70 | 0.16 | Why? |
| Neuroprotection | 1 | 2017 | 62 | 0.16 | Why? |
| Sampling Studies | 1 | 2018 | 386 | 0.16 | Why? |
| Levodopa | 2 | 2017 | 87 | 0.16 | Why? |
| Hearing Loss, Sensorineural | 1 | 2019 | 159 | 0.16 | Why? |
| Psoriasis | 2 | 2021 | 1739 | 0.16 | Why? |
| Receptors, Nicotinic | 1 | 2017 | 81 | 0.16 | Why? |
| Dermatitis, Occupational | 1 | 2021 | 310 | 0.15 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| Antiparkinson Agents | 2 | 2017 | 125 | 0.15 | Why? |
| Endogenous Retroviruses | 1 | 2015 | 72 | 0.15 | Why? |
| Radiotherapy, Adjuvant | 1 | 2016 | 180 | 0.15 | Why? |
| Blood Cell Count | 1 | 2021 | 1101 | 0.15 | Why? |
| Dermatologic Surgical Procedures | 1 | 2017 | 138 | 0.14 | Why? |
| Humans | 33 | 2021 | 930598 | 0.14 | Why? |
| Receptors, G-Protein-Coupled | 1 | 2018 | 309 | 0.14 | Why? |
| Adult | 15 | 2021 | 244371 | 0.14 | Why? |
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 121 | 0.13 | Why? |
| Masks | 3 | 2021 | 8528 | 0.13 | Why? |
| Receptors, Dopamine D1 | 1 | 2013 | 9 | 0.13 | Why? |
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2013 | 14 | 0.13 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.13 | Why? |
| Quality of Life | 3 | 2021 | 9820 | 0.13 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.13 | Why? |
| Thyroid Diseases | 1 | 2017 | 285 | 0.13 | Why? |
| Dermatitis, Atopic | 1 | 2021 | 714 | 0.12 | Why? |
| Diagnosis, Differential | 2 | 2019 | 7220 | 0.12 | Why? |
| Female | 18 | 2021 | 380317 | 0.12 | Why? |
| Immunohistochemistry | 2 | 2018 | 2275 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| Emigration and Immigration | 1 | 2017 | 501 | 0.11 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.11 | Why? |
| Nitric Oxide | 1 | 2018 | 769 | 0.11 | Why? |
| Mitochondria | 1 | 2018 | 857 | 0.11 | Why? |
| Aged | 12 | 2021 | 215776 | 0.11 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.10 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.10 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.10 | Why? |
| Male | 17 | 2021 | 367725 | 0.10 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.10 | Why? |
| Protein Kinase Inhibitors | 1 | 2019 | 1585 | 0.09 | Why? |
| Immunoglobulins, Intravenous | 1 | 2021 | 2705 | 0.09 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.09 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.09 | Why? |
| Prognosis | 5 | 2021 | 32490 | 0.09 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.09 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.09 | Why? |
| Tyrosine 3-Monooxygenase | 2 | 2017 | 32 | 0.09 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.09 | Why? |
| Interferon-alpha | 1 | 2016 | 1442 | 0.09 | Why? |
| Referral and Consultation | 2 | 2021 | 4816 | 0.08 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.08 | Why? |
| Oxidopamine | 2 | 2017 | 9 | 0.08 | Why? |
| Adrenergic Agents | 2 | 2017 | 7 | 0.08 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.08 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.07 | Why? |
| Recombinant Proteins | 1 | 2016 | 3786 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.07 | Why? |
| Parkinson Disease | 1 | 2017 | 1414 | 0.07 | Why? |
| Immunophenotyping | 1 | 2008 | 1290 | 0.06 | Why? |
| Antigens, CD | 1 | 2008 | 984 | 0.06 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.06 | Why? |
| Organ Transplantation | 1 | 2018 | 2616 | 0.06 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.06 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.06 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.06 | Why? |
| Receptors, Interleukin | 1 | 2021 | 83 | 0.05 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.05 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.05 | Why? |
| Flow Cytometry | 1 | 2008 | 2393 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Copper-Transporting ATPases | 1 | 2017 | 8 | 0.05 | Why? |
| DNA Repair | 1 | 2018 | 114 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Skull | 1 | 2017 | 48 | 0.04 | Why? |
| Bioluminescence Resonance Energy Transfer Techniques | 1 | 2017 | 1 | 0.04 | Why? |
| Psychomotor Disorders | 1 | 2017 | 5 | 0.04 | Why? |
| Benserazide | 1 | 2017 | 4 | 0.04 | Why? |
| Quinpirole | 1 | 2017 | 4 | 0.04 | Why? |
| Cell Shape | 1 | 2017 | 57 | 0.04 | Why? |
| Exons | 1 | 2017 | 158 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Cerebral Arteries | 1 | 2017 | 90 | 0.04 | Why? |
| Functional Laterality | 1 | 2017 | 57 | 0.04 | Why? |
| Rats | 2 | 2017 | 2764 | 0.04 | Why? |
| Benzazepines | 1 | 2017 | 49 | 0.04 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.04 | Why? |
| Nicotinic Agonists | 1 | 2017 | 56 | 0.04 | Why? |
| Dopamine Agonists | 1 | 2017 | 61 | 0.04 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.04 | Why? |
| Dopamine | 1 | 2017 | 123 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Animals | 4 | 2019 | 78931 | 0.04 | Why? |
| Interleukin-17 | 1 | 2021 | 602 | 0.04 | Why? |
| Chronic Disease | 2 | 2021 | 5139 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.04 | Why? |
| Green Fluorescent Proteins | 1 | 2017 | 450 | 0.04 | Why? |
| Lymphocytes | 1 | 2008 | 3056 | 0.04 | Why? |
| Point Mutation | 1 | 2017 | 481 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.03 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.03 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.03 | Why? |
| Nicotine | 1 | 2017 | 213 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Rats, Sprague-Dawley | 1 | 2017 | 987 | 0.03 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.03 | Why? |
| Immunoprecipitation | 1 | 2013 | 300 | 0.03 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2017 | 584 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Parkinsonian Disorders | 1 | 2013 | 118 | 0.03 | Why? |
| Rats, Wistar | 1 | 2013 | 621 | 0.03 | Why? |
| Protein Multimerization | 1 | 2017 | 1336 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.03 | Why? |
| Blotting, Western | 1 | 2013 | 863 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Transcription, Genetic | 1 | 2015 | 1326 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.02 | Why? |
| RNA, Viral | 1 | 2015 | 32276 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Smoking | 1 | 2020 | 3358 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
Savoia's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(221)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_